Best Foods on Ozempic: Biomarker-Guided Nutrition

Last reviewed: June 1, 2026

Last updated: June 1, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

GLP-1 therapy like semaglutide and tirzepatide works best when paired with strategic nutrition—but the best foods vary significantly between individuals based on gastrointestinal tolerance, metabolic markers, and genetic predispositions. Research shows that patients who align dietary choices with their biomarker profile experience fewer adverse effects and better treatment adherence.

PlexusDx believes precision nutrition during GLP-1 therapy should rest on two pillars: clinical evidence and individual biomarker context. Understanding your genetic predispositions in peptide signaling pathways can inform whether you tolerate higher-protein foods, complex carbohydrates, or require more gradual dietary transitions—moving you beyond generic food lists toward a plan tailored to your physiology.

How GLP-1 Alters Appetite and Digestion: Why Food Tolerance Matters

GLP-1 receptor agonists slow gastric emptying and increase satiety signals, which fundamentally changes how your body processes and tolerates food. This mechanism can cause early fullness, nausea, or constipation—meaning the 'best' food isn't always the most nutritious, but what your current physiology can handle without discomfort.

Biomarkers like baseline gastric motility, ghrelin levels, and inflammatory markers provide clinical context for predicting your tolerance window. Patients with slower baseline gastric emptying may require softer, lower-fat foods initially, while others transition to regular textures within weeks. Discussing these markers with your provider helps set realistic dietary expectations.

Food Categories by Tolerance Phase and Biomarker Context

Nutrition during GLP-1 therapy typically progresses through phases: early tolerance (soft, low-fat), maintenance (balanced macros), and optimization (high-protein, fiber-rich). Your biomarker profile and genetic predispositions in key peptide pathways help identify which phase fits your starting point and how quickly you might advance.

Food Category	Early Phase (Weeks 1–4)	Maintenance Phase (Weeks 5–12)	Why Biomarkers Matter
Proteins	Egg whites, soft tofu, Greek yogurt (20–25g per meal)	Lean poultry, fish, cottage cheese (25–35g per meal)	Proteolytic enzyme activity and MC4R variants influence protein tolerance and satiety response
Carbohydrates	White rice, refined pasta, plain crackers	Oats, sweet potato, legumes, whole grain bread	GLP1R and FTO genetic variants correlate with carb sensitivity and glycemic response
Fats	Minimal (0–5g per meal initially)	Olive oil, avocado, nuts (5–10g per meal)	Delayed gastric emptying means fat intake tolerance varies widely; biomarkers guide pacing
Fiber	Minimal (avoid high-fiber initially)	Gradual increase to 25–30g daily from vegetables, whole grains	GIPR rs1800437 variant predicts GLP-1 induced motility—impacts safe fiber progression

Genetic Predispositions and Nutrient Absorption: Beyond Standard Guidelines

Your genetic background in GLP-1 receptor signaling (GLP1R rs6923761), glucose-sensing pathways (GIPR rs1800437), and appetite regulation (MC4R rs17782313, FTO rs9939609) influences how efficiently your body absorbs nutrients and responds to macronutrient ratios. Standard nutrition advice assumes average gene expression, but variant carriers may require different strategies.

For example, individuals with specific FTO variants may experience stronger appetite suppression and benefit from higher-protein intake to prevent catabolism. Conversely, GIPR variant carriers might tolerate incremental carbohydrate introduction more readily. A provider-informed biomarker assessment clarifies these individual patterns, moving nutrition from guesswork to evidence-guided personalization.

Foods to Prioritize and Avoid: Clinical Safety and Evidence

Prioritize nutrient-dense, low-fat, and easily digestible foods: lean proteins, non-starchy vegetables, soft fruits, yogurt, and whole grains introduced gradually. Avoid high-fat processed foods, sugary items, and large portions—which trigger nausea and counteract GLP-1's satiety benefits. Evidence shows patients who emphasize whole foods report fewer gastrointestinal side effects and better weight-loss outcomes.

Individual tolerance varies significantly. Some patients thrive on plant-based proteins early; others need animal proteins for adequate amino acid absorption. Hydration is critical—GLP-1 increases dehydration risk. Work with a healthcare provider to monitor micronutrient status (B12, folate, iron) and adjust nutrition periodically as your tolerance phase advances and biomarker changes occur.

When to Seek Provider Guidance: Red Flags and Biomarker Monitoring

Contact your provider if you experience persistent nausea beyond two weeks, severe constipation, unintended rapid weight loss (>2 lbs/week), or signs of nutrient deficiency (fatigue, hair loss, brittle nails). These symptoms suggest your current nutrition approach doesn't align with your biomarker profile or medication tolerance, and dosing or dietary adjustments may be warranted.

Regular biomarker monitoring—electrolytes, albumin, B12, iron—helps catch deficiencies early during GLP-1 therapy. Genetic testing for peptide pathway predispositions can inform your provider's initial nutrition guidance and medication selection, supporting a more individualized treatment strategy from the outset.

How PlexusDx Supports a More Personalized Approach

PlexusDx's Precision Peptide Genetic Test may help provide context for your nutritional tolerance during GLP-1 therapy by revealing predispositions in key appetite and glucose-sensing pathways. Variants in GLP1R, GIPR, MC4R, and FTO influence how your body signals fullness, processes macronutrients, and manages weight loss—information that can support a more informed conversation with your provider about dietary pacing and macro ratios.

The genetic test does not predict your exact medication response or guarantee specific food tolerances. Rather, it identifies genetic predispositions that correlate with appetite signaling efficiency and metabolic flexibility. This context, combined with your current biomarkers (gastric motility, ghrelin, inflammatory markers) and clinical presentation, helps your provider craft a nutrition strategy aligned with your physiology rather than generic guidelines.

If you're considering GLP-1 therapy through PlexusDx—whether compounded semaglutide injection, oral semaglutide, compounded tirzepatide, or oral tirzepatide options—pairing your treatment with a Precision Peptide Genetic Test ($99 add-on or $298 standalone) can support a comprehensive provider consultation about nutrition, dosing, and long-term adherence. This integration of genetics, biomarkers, and clinical evidence positions you for more sustainable outcomes.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Oral starts at $229-$509/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.